CO99 Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Utilization Patterns for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among United States (US) Community Hematologists/Oncologists (CH/OS)

Patients with R/R DLBCL are initially treated by cH/Os and require referral for CAR-T. Aspects of the patient’s complex journey not well understood. This study assessed CAR-T recipient care from cH/O perspective. was a retrospective, observational, multicenter recipients in 2019. Charts were abstracted treating capturing treatment patterns outcomes. Data compared months initial diagnosis to (≤18 [n=29] or >18 [n=36]) using <18-month surrogate endpoint poor prognosis (e.g., refractory disease, rapid progression) chi-square, Fisher exact, t-tests. also described patients’ US regions. 13 identified 65 patients. Most (92%) received first-line R + CHOP, had median 2 pre-CAR-T therapies (range 1-4), 32% prior autologous stem cell transplantation (ASCT), 60% axicabtagene ciloleucel (axi-cel), 39% tisagenlecleucel (tisa-cel), 2% lisocabtagene maraleucel. between more likely receive ASCT (53% vs 7%, P=0.0056) have longer overall survival (OS) post-CAR-T (64.8 40.3 months, P=0.0488). Median times key events sample were: leukapheresis (LP), 4.6 weeks; LP CAR-T, 3.6 weeks. Patient distributions within each region Northeast [NE] (n=19, 29%), Midwest [MW] (n=6, 9%), South [S] (n=14, 22%), West [W] (n=26, 40%), respectively, time ≤18 (n=29, 45%): 74%), (n=2, 33%), 14%), (n=11, 42%) (P=0.0056); (n=21, 32%): 11%), (n=5, 83%), (n=10, 71%), (n=4, 15%) (P<0.0001); axi-cel (n=39, 60%): (n=9, 47%), (n=1, 17%), 100%), (n=15, 58%) (P=0.0006); tisa-cel (n=25, 39%): 53%), (n=0, 0%), 39%) (P=0.0006). Regional differences important outcomes observed. Shorter OS is consistent recent trials.